Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.32 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.32 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.32 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046539 | 0.87 | HTT (0.45) | HTTPGRMRGPRX4TAS2R14PLAAT3 | |
| SCHEMBL5726591 | 0.84 | BMP1 (0.34) | KDM4EHSP90AA1HSP90AB1TAAR1 | |
| SCHEMBL5725632 | 0.84 | KDM4E (0.35) | MRGPRX4KDM4EHSP90AA1HSP90AB1TAAR1 | |
| SCHEMBL5043024 | 0.82 | KDM4E (0.37) | HTTMRGPRX4KDM4EPLAAT3PLAAT5 | |
| SCHEMBL5727081 | 0.82 | GRM5 (0.38) | MRGPRX4KDM4EHSP90AA1HSP90AB1TAAR1 | |
| SCHEMBL5046412 | 0.81 | KDM4E (0.40) | MRGPRX4TAS2R14KDM4EPLAAT3PLAAT5 | |
| SCHEMBL5043004 | 0.80 | KDM4E (0.41) | HTTMRGPRX4KDM4EPLAAT3PLAAT5 | |
| SCHEMBL5047973 | 0.78 | LMNA (0.46) | HTTTAS2R14PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL7227270 | 0.78 | MRGPRX4 (0.44) | HTTMRGPRX4KDM4EPLAAT3PLAAT5 | |
| SCHEMBL5043363 | 0.78 | TAS2R14 (0.39) | HTTNR1D1TAS2R14KDM4EPLAAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1601351-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2004078169-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | HTT 2486/4885PGR 241/4885NR1D1 838/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | HTT 4421/4885PGR 136/4885NR1D1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.